Cargando…

MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer

Elucidating the adaptive mechanisms that prevent host immune response in cancer will help predict efficacy of anti-programmed death-1 (PD1)/L1 therapies. Here, we study the cell-intrinsic response of lung cancer (LC) to interferon-γ (IFNγ), a cytokine that promotes immunoresponse and modulates progr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alburquerque-Bejar, Juan J., Navajas-Chocarro, Pablo, Saigi, Maria, Ferrero-Andres, Ana, Morillas, Juan M., Vilarrubi, Andrea, Gomez, Antonio, Mate, José L., Munoz-Marmol, Ana M., Romero, Octavio A., Blecua, Pedro, Davalos, Veronica, Esteller, Manel, Pros, Eva, Llabata, Paula, Torres-Diz, Manuel, Esteve-Codina, Anna, Sanchez-Cespedes, Montse
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140599/ https://www.ncbi.nlm.nih.gov/pubmed/37044092 http://dx.doi.org/10.1016/j.xcrm.2023.101006

Ejemplares similares

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade
por: Romero, Octavio A., et al.
Publicado: (2021)

Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells
por: Gimenez-Xavier, Pol, et al.
Publicado: (2018)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C
por: Notario, Lucía, et al.
Publicado: (2023)

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
por: Zuazo, Miren, et al.
Publicado: (2020)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
por: Zuazo, Miren, et al.
Publicado: (2020)

The DNA methylation landscape of hematological malignancies: an update
por: Blecua, Pedro, et al.
Publicado: (2020)

Refinement of computational identification of somatic copy number alterations using DNA methylation microarrays illustrated in cancers of unknown primary
por: Blecua, Pedro, et al.
Publicado: (2022)

Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver
por: Domènech, Marta, et al.
Publicado: (2021)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
por: Chocarro de Erauso, Luisa, et al.
Publicado: (2020)

Immunosuppression in Gliomas via PD-1/PD-L1 Axis and Adenosine Pathway
por: Scheffel, Thamiris Becker, et al.
Publicado: (2021)

Plasma fractalkine contributes to systemic myeloid diversity and PD‐L1/PD‐1 blockade in lung cancer
por: Bocanegra, Ana, et al.
Publicado: (2023)

Insights from the genetic and transcriptional characterization of a cancer of unknown primary (CUP)
por: Davalos, Veronica, et al.
Publicado: (2020)

PD-1 signaling affects cristae morphology and leads to mitochondrial dysfunction in human CD8(+) T lymphocytes
por: Ogando, Jesús, et al.
Publicado: (2019)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
por: Zalba, Sara, et al.
Publicado: (2020)

Vibrational Properties of Pd Nanocubes
por: Flor, Alberto, et al.
Publicado: (2019)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

PD-1/CTLA-4 Blockade Leads to Expansion of CD8(+)PD-1(int) TILs and Results in Tumor Remission in Experimental Liver Cancer
por: Bufe, Sandra, et al.
Publicado: (2022)

Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients
por: Arrieta, Oscar, et al.
Publicado: (2017)

DLL3 Is a Prognostic and Potentially Predictive Biomarker for Immunotherapy Linked to PD/PD-L Axis and NOTCH1 in Pancreatic Cancer
por: Lacalle-Gonzalez, Carlos, et al.
Publicado: (2023)

Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade
por: Serganova, Inna, et al.
Publicado: (2016)

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
por: Jimbu, Laura, et al.
Publicado: (2021)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

A Facile Preparation of Sandwich-Structured Pd/Polypyrrole-Graphene/Pd Catalysts for Formic Acid Electro-Oxidation
por: Lu, Zhenjiang, et al.
Publicado: (2023)

C–H arylation of triphenylene, naphthalene and related arenes using Pd/C
por: Collins, Karl D., et al.
Publicado: (2015)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Risk of immune‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis
por: Huang, Yafang, et al.
Publicado: (2019)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and CO(PD) of Marbofloxacin against Haemophilus parasuis
por: Sun, Jian, et al.
Publicado: (2015)

CTHRC1 and PD-1/PD-L1 expression predicts tumor recurrence in prostate cancer
por: Zhou, Qing, et al.
Publicado: (2019)

Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis
por: Huang, Ya-fang, et al.
Publicado: (2019)

PD11 - Omalizumab in children: experience in the Immunoallergology Department
por: Aguiar, Rita, et al.
Publicado: (2014)

Emission properties of Pd-doped CsPbBr(3) perovskite nanocrystal: Infrared emission due to the Pd-doping
por: Rodríguez-Fernández, Mabel, et al.
Publicado: (2023)

Imaging of Dopamine in PD and Implications for Motor and Neuropsychiatric Manifestations of PD
por: de la Fuente-Fernández, Raúl
Publicado: (2013)

The Evolution of Pd(0)/Pd(II)-Catalyzed Aromatic Fluorination
por: Sather, Aaron C., et al.
Publicado: (2016)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7oltr5nttkli8j00voap0qre3d